- Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for.
- BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors.
- SAVA's simufilam Phase 3 trials are getting underway setting the stage for a big binary stock event for speculative investors to bet on.
- Upcoming events should lead to continued volatility in both stocks likely making them unsuitable for risk-intolerant investors.
For further details see:
Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?